Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

December 13, 2022

Study Completion Date

January 13, 2023

Conditions

Healthy

Interventions

DRUG

Gleptomet 50/1000(Metformin HCl & Sitagliptin)

Test drug

DRUG

Janumet 50/1000(Metformin HCl & Sitagliptin)

Reference drug

Trial Locations (1)

Genuine Research Center GRC, Cairo